8-K: Vaxart Secures $453 Million BARDA Contract, Advances Oral COVID-19 Vaccine

Vaxart announced a significant BARDA contract of up to $453 million to support a Phase 2b trial for its oral COVID-19 vaccine, alongside positive Phase 1 data for its norovirus vaccine and an extended cash runway.

Summary

• Vaxart has received a BARDA contract worth up to $453 million to fund a Phase 2b trial for its oral COVID-19 vaccine.
• The Phase 2b trial will compare Vaxart's oral vaccine against an approved mRNA injectable vaccine and will involve 10,000 participants.
• An interim analysis of the trial may occur after 255 symptomatic COVID-19 cases are observed, with the primary analysis at 12 months post-vaccination.
• Vaxart also reported positive Phase 1 data for its bivalent norovirus vaccine in lactating mothers.
• The company's cash, cash equivalents, and investments totaled $62.6 million as of June 30, 2024, with an additional $64.7 million received after the quarter related to the BARDA contract.
• Vaxart anticipates its cash runway will extend into 2026.
• The company reported a net loss of $16.5 million for the second quarter of 2024, an improvement from the $22.6 million loss in the same quarter of 2023.
• Revenue for the second quarter of 2024 was $6.4 million, compared to $1.4 million in the second quarter of 2023, primarily from government contracts.
• Research and development expenses were $17.5 million for the second quarter of 2024, down from $18.8 million in the same period of 2023.

Sentiment

Score: 8

Explanation: The document is highly positive due to the large BARDA contract, positive clinical data, and improved financial results. The company is well-funded and making progress on its key programs.

Positives

• The $453 million BARDA contract significantly funds the Phase 2b COVID-19 vaccine trial.
• Positive Phase 1 data for the norovirus vaccine indicates potential for further development.
• The company's cash position is strong, with a runway into 2026.
• Revenue increased significantly year-over-year, primarily due to government contracts.
• The net loss decreased compared to the same quarter last year, indicating improved financial performance.

Negatives

• The company reported a net loss of $16.5 million for the second quarter of 2024.
• Research and development expenses remain high at $17.5 million for the quarter.

Risks

• The Phase 2b trial for the COVID-19 vaccine is subject to regulatory alignment with the FDA.
• The norovirus vaccine program's next steps depend on ongoing discussions with the FDA.
• The company's future success depends on the successful development and commercialization of its vaccine candidates.
• There are inherent risks in research and development, including the ability to meet clinical endpoints and regulatory approvals.
• The company may face challenges in scaling up production and maintaining quality control.

Future Outlook

Vaxart plans to initiate enrollment in the Phase 2b COVID-19 trial in the near-term, pending regulatory alignment with the FDA, and will determine next steps for the norovirus program based on discussions with the FDA. The company anticipates its cash runway will extend into 2026.

Management Comments

• We achieved meaningful progress on our clinical, regulatory and operational goals during the first half of 2024, said Steven Lo, Vaxarts Chief Executive Officer.
• Most significant was one of the largest Biomedical Advanced Research Development Authority (BARDA) contracts awarded to date for our COVID-19 program under Project NextGen providing up to $453 million to support a Phase 2b trial.
• Through our focus on execution and continued constructive conversations with the U.S. Food and Drug Administration (FDA), we are well-positioned to initiate our COVID Phase 2b trial in the near-term and determine next steps in advancing our norovirus program, Lo added.
• We believe that by unlocking the potential of our oral pill vaccine platform, we will have a solution that can solve some of the greatest global health problems today.

Industry Context

This announcement highlights the ongoing efforts in developing next-generation vaccines, particularly oral vaccines, to combat infectious diseases like COVID-19 and norovirus. The BARDA contract underscores the government's interest in innovative vaccine technologies. Vaxart's approach aligns with the broader industry trend of exploring alternative vaccine delivery methods.

Comparison to Industry Standards

• Vaxart's $453 million BARDA contract is a significant funding event, comparable to other large government grants for vaccine development, such as those awarded to Moderna and Pfizer during the initial COVID-19 vaccine push.
• The Phase 2b trial size of 10,000 participants is substantial, aligning with industry standards for late-stage vaccine trials, similar to the scale of trials conducted by Novavax and AstraZeneca.
• The focus on an oral vaccine platform differentiates Vaxart from most other vaccine developers, who primarily use injectable methods, putting them in a similar category to companies like Oramed Pharmaceuticals, which are also exploring oral delivery systems.
• Vaxart's revenue increase from $1.4 million to $6.4 million year-over-year is a positive sign, but still relatively low compared to established pharmaceutical companies with commercialized products, such as Gilead Sciences or Regeneron Pharmaceuticals.
• The net loss of $16.5 million is typical for a clinical-stage biotech company, and is similar to other companies in the same stage of development, such as Inovio Pharmaceuticals or Dynavax Technologies.

Stakeholder Impact

• Shareholders will likely view the BARDA contract and improved financial results positively.
• Employees may benefit from the increased funding and progress in clinical programs.
• Customers (potential patients) may benefit from the development of new oral vaccines.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may view the company as a lower risk due to the improved financial position.

Next Steps

• Vaxart plans to initiate enrollment in the Phase 2b COVID-19 trial in the near-term.
• The company will continue discussions with the FDA regarding the norovirus vaccine program.
• Vaxart will submit additional requested information to the FDA for the norovirus vaccine.
• The company will determine next steps for the norovirus program, potentially including a Phase 2b study or a GII.4 challenge study.

Key Dates

Keywords

Vaxart, COVID-19 vaccine, oral vaccine, BARDA, Phase 2b trial, norovirus vaccine, clinical trial, biotechnology, infectious diseases, vaccine development